MGAM2 is a putative maltase-glucoamylase family member with divergent structure and function from its paralog MGAM 1. Unlike MGAM, which retains α-1,4-glucosidase activity for intestinal starch digestion, MGAM2 has likely lost glucosidase catalytic activity in placental mammals due to mutations in key catalytic residues 1. Instead, MGAM2 possesses a unique extracellular, threonine-rich, evolutionarily hypervariable (EHV) domain 1, suggesting an altered biological role distinct from carbohydrate hydrolysis. MGAM2 is implicated in glucose metabolism regulation. Genome-wide association studies identified MGAM2 variants associated with 1,5-anhydroglucitol concentrations, a biomarker of hyperglycemic excursions 2. Genetic variation in MGAM2 correlates with dietary carbohydrate restriction efficacy in irritable bowel syndrome patients, particularly the IBS-diarrheal subtype 3. Clinically, MGAM2 expression is nearly exclusive to basal-like breast cancers and associates with improved patient survival, correlating with immune-related gene signatures 1. MGAM2 mutations appear relevant to colorectal cancer pedigrees with concurrent gastric cancer 4 and represent recurrent alterations in ductal carcinoma in situ 5. These findings suggest MGAM2 functions in immune regulation and metabolic pathways affecting carbohydrate handling and cancer progression, warranting further mechanistic investigation.